Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Consensus Target Price of $56.00 According to Brokerages

Shares of Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) have been given a consensus rating of “Buy” by the six ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $53.00.

Several equities research analysts recently weighed in on KRSA shares. Stifel Nicolaus started coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating and a $43.00 target price for the company. Wedbush began coverage on Cyclerion Therapeutics in a research note on Monday. They set an “outperform” rating and a $44.00 price objective for the company. TD Cowen began coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating on the stock. Wall Street Zen raised shares of Cyclerion Therapeutics to a “sell” rating in a report on Saturday, October 3rd. Finally, Guggenheim assumed coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 28th. They set a “buy” rating and a $70.00 target price for the company.

Cyclerion Therapeutics Price Performance

KRSA opened at $31.65 on Friday. Cyclerion Therapeutics has a 1-year low of $7.19 and a 1-year high of $59.36. The company has a market capitalization of $21.21 million, a PE ratio of -2.72 and a beta of 1.72.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function.

Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease.